Expanding MRI Access for Patients With New and Existing ICDs and CRT-Ds ( ENABLE MRI) (ENABLE MRI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02652481
Recruitment Status : Active, not recruiting
First Posted : January 12, 2016
Last Update Posted : November 20, 2017
Information provided by (Responsible Party):
Boston Scientific Corporation

Brief Summary:

The objective of this study is to collect data to confirm the safety and effectiveness of the ImageReady™ MR Conditional Defibrillation System when used in the 1.5T MRI environment under the labeled Conditions of Use (Phase I).

Additionally, the study will assess medically necessary MR scans according to the labeled Conditions of Use to provide real-world scanning data (Phase I and Phase II).

The study also aims to demonstrate the continued ability of the ImageReady MR Conditional Defibrillation System to sense and detect ventricular fibrillation (VF) post MRI scan by collecting and analyzing data from spontaneous VF episodes, "for-cause" VF inductions, and from an optional VF induction Sub-study.

Condition or disease Intervention/treatment Phase
Magnetic Resonance Imaging Device: ImageReady MR Conditional Defibrillation System Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Study Start Date : January 2016
Actual Primary Completion Date : April 30, 2017
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: MRI Scans

Arm Intervention/treatment
open label - 1 arm
prospective, non-randomized, confirmatory study
Device: ImageReady MR Conditional Defibrillation System

ImageReady MR Conditional Defibrillation System Components:

Device Name Device Model Number Pulse Generators Phase I and II Phase II Only * CRT-D (IS1/DF4/IS4) VR ICD (DF4) DR ICD (IS1/DF4) ORIGEN™ MINI ICD ORIGEN EL ICD ORIGEN X4 CRT INOGEN™ MINI ICD INOGEN EL ICD INOGEN X4 CRT DYNAGEN™ MINI ICD DYNAGEN EL ICD DYNAGEN X4 CRT-D AUTOGEN ™ MINI ICD* AUTOGEN EL ICD* AUTOGEN X4 CRT-D* Right Atrial Leads and Accessories FINELINE™ II Sterox FINELINE II Sterox EZ Suture Sleeves for FINELINE II Leads INGEVITY™ MRI* Suture Sleeve for INGEVITY MRI* IS-1 Lead Port Plug 7145 Right Ventricular Leads and Accessories RELIANCE 4-FRONT™ (DF4)* Suture Sleeve for RELIANCE 4-FRONT leads*; ENDOTAK RELIANCE™ (DF4) Left Ventricular Leads and Accessories ACUITY™ X4 (IS4) Suture Sleeve for ACUITY X4 leads

* May only be used internationally outside the US

Primary Outcome Measures :
  1. MR scan-related System Complication Free Rate (CFR) [ Time Frame: 1 Month ]
    MR scan-related Complication-free rate between the MR Scan and the MRI + 1 Month Visit

  2. Increase in RV pacing threshold [ Time Frame: 1 Month ]
    Increase in RV pacing threshold from the pre-MR scan to the 1 Month post-MR scan

  3. Increase in LV pacing threshold [ Time Frame: 1 Month ]
    Increase in LV pacing threshold from the pre-MR scan to the 1 Monthpost-MR scan

  4. Decrease in RV sensed amplitude [ Time Frame: 1 Month ]
    Decrease in RV sensed amplitude from the pre-MR scan to the 1 Month post-MR scan

  5. Decrease in LV sensed amplitude [ Time Frame: 1 Month ]
    Decrease in LV sensed amplitude from the pre-MR scan to the 1 Month post-MR scan

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  1. Phase I: Subject is indicated per guidelines and will receive a CRT-D or ICD system OR Subject is implanted with a functional and stable CRT-D or ICD system Phase II: Subject is implanted with a functional and stable CRT-D or ICD system
  2. Subject will receive or is implanted with an ICD or CRT-D pulse generator in the left or right pectoral region
  3. Subject is able and willing to undergo an MR scan without intravenous sedation (Phase I only)
  4. Subject is willing and capable of providing informed consent and participating in all testing/ visits associated with this clinical study at an approved clinical study center and at the intervals defined by this protocol
  5. Subject is age 18 or above, or of legal age to give informed consent specific to state and national law

Key Exclusion Criteria:

  1. Subject implanted with an ICD or CRT-D pulse generator with battery at Explant status
  2. Subject has other active or abandoned implanted cardiac rhythm devices, components or accessories present such as pulse generators, leads, lead adaptors or extenders
  3. Presence of metallic objects that represent a contraindication to MR imaging at the discretion of the Radiologist and impacting the ability to conduct the study protocol
  4. Subject needs or will need a medically necessary MR scan, before completing the 1-month post-MR follow-up visit (Phase I only)
  5. Subject with:

    • A history of syncope related to brady-arrhythmia
    • A history of syncope of unknown etiology
    • Sinus pauses (Pause > 2 s)
    • Permanent or intermittent complete AV block
    • Documentation of progressive AV nodal block over time
    • Trifascicular block (alternating bundle branch block or PR > 200 ms with LBBB or other bifascicular block) Note: It is required to run a 12 lead ECG and a 10s rhythm strip to document this exclusion criterion. During ECG acquisition, subjects must be in either their own intrinsic rhythm or, in subjects with an existing device implant, the device must be programmed to VVI 40 ppm.
  6. Subject is not clinically capable of tolerating the absence of pacing or Resynchronization therapy support in a supine position for the duration that the pulse generator is in MRI Protection Mode, per Physician discretion
  7. Subject is not clinically capable of tolerating the absence of Tachycardia therapy support for the duration that the pulse generator is in MRI Protection Mode, per Physician discretion
  8. Subjects with a planned RA, RV or LV lead revision or extraction within 30 days of enrollment (Phase I only)
  9. Subjects with an implanted lead that is planned to be extracted during the study implant procedure
  10. Subjects currently requiring dialysis
  11. Subject has a mechanical heart valve
  12. Subject has a known or suspected sensitivity to dexamethasone acetate (DXA)
  13. Subject is currently on the active heart transplant list
  14. Subject has documented life expectancy of less than 12 months
  15. Subject is enrolled in a concurrent study, with the exception of local mandatory governmental registries and observational studies/registries, without the written approval from Boston Scientific
  16. Women of childbearing potential who are or might be pregnant, and will receive an ICD or CRT-D pulse generator

VF Induction Sub-study Exclusion Criteria:

In addition to meeting all of the inclusion criteria and none of the exclusion criteria of the ENABLE MRI study, subjects enrolled in the VF Induction Sub-study must also not meet any of the following VF Induction Sub-study exclusion criteria:

  1. Unstable heart failure requiring hospitalization in the last 30 calendar days
  2. Unable to tolerate sedation (e.g. IV sedation, general anesthesia)
  3. Planned cardiac revascularization procedure
  4. Right Ventricular Lead R wave is less than 5 mV

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02652481

  Hide Study Locations
United States, Alabama
Heart Center Research, LLC
Huntsville, Alabama, United States
United States, Arkansas
Cardiology Associates of Northeast Arkansas
Jonesboro, Arkansas, United States
United States, California
Huntington Memorial Hospital
Pasadena, California, United States
University of California - San Diego-N
San Diego, California, United States
John Muir Medical Center
Walnut Creek, California, United States
United States, Florida
Manatee Memorial Hospital
Bradenton, Florida, United States
Lakeland Regional Medical Center
Lakeland, Florida, United States
University Community Hospital
Tampa, Florida, United States
United States, Georgia
Emory University Hospital
Atlanta, Georgia, United States
United States, Illinois
St. John's hospital
Springfield, Illinois, United States
United States, Indiana
St. Vincent's Hospital
Indianapolis, Indiana, United States
United States, Iowa
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
United States, Michigan
Marquette General Hospital
Marquette, Michigan, United States
United States, Minnesota
Centracare Heart and Vascular Center
Saint Cloud, Minnesota, United States
HealthEast St. Joseph's Hospital
Saint Paul, Minnesota, United States
United States, Mississippi
North Mississippi Medical Center
Tupelo, Mississippi, United States
United States, Missouri
Cox Health
Springfield, Missouri, United States
United States, New York
Northwell Health
New York, New York, United States
United States, North Carolina
University of North Carolina Hospital
Chapel Hills, North Carolina, United States
United States, Ohio
OhioHealth Research and Innovation Institute - Riverside Methodist Hospital
Columbus, Ohio, United States
The Toledo Hospital
Toledo, Ohio, United States
United States, Oregon
Providence St. Vincent Medical Center
Portland, Oregon, United States
United States, Pennsylvania
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
United States, South Dakota
Rapid City Regional Hospital
Rapid City, South Dakota, United States
United States, Tennessee
St. Thomas Research Institute, LLC
Nashville, Tennessee, United States
United States, Texas
SouthEast Texas Clinical Research Center
Beaumont, Texas, United States
University of Texas Houston Health Science Center
The Woodlands, Texas, United States
Trinity Mother Frances Health System
Tyler, Texas, United States
United States, Utah
University of Utah Hospital and Clinics
Salt Lake City, Utah, United States
United States, Virginia
Sentara Norfolk General Hospital
Norfolk, Virginia, United States
Virginia Commonwealth University Health System
Richmond, Virginia, United States
United States, Washington
Providence Regional Medical Center Everett
Everett, Washington, United States
PeaceHealth Southwest Medical
Vancouver, Washington, United States
Academisch Ziekenhuis Middelheim
Antwerp, Belgium
Deutsches Herzzentrum Berlin
Berlin, Germany
Medizinische Hochschule Hannover MHH
Hannover, Germany
Klinikum Magdeburg
Magdeburg, Germany
Hong Kong
Prince of Wales Hospital
Hong Kong, Hong Kong
Queen Mary Hospital
Hong Kong, Hong Kong
Rambam Medical Center
Haifa, Israel
Soroka MC
Petah Tikva, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Hadassah Hebrew University Medical Center
Tel Hashomer, Israel
Fondazione di Ricerca e Cura 'Giovanni Paolo II'
Campobasso, Italy
Azienda Ospedaliera Universitaria Federico II
Napoli, Italy
Azienda Ospedaliera San Camillo-Forlanini
Roma, Italy
Ospedale S.G. Calibita Fatebenefratelli - Isola Tiberina
Roma, Italy
Policlinico Casilino
Roma, Italy
Ospedale san giovanni calibita
Tiberina, Italy
Osp. S. Maria Della Misericordia
Udine, Italy
Institut Jantung Negara
Kuala Lumpur, Malaysia
University of Malaya Medical Centre
Kuala Lumpur, Malaysia
Bryn Mawr Medical Specialists
Bryn Mawr, Palau
Hospital Clinic de Barcelona
Barcelona, Spain
United Kingdom
Heart and Chest Hospital
Liverpool, United Kingdom
Guys and St. Thomas NHS Foundation Trust
London, United Kingdom
Freeman Hospital
Newcastle, United Kingdom
Sponsors and Collaborators
Boston Scientific Corporation
Study Director: Gregory Voss Boston Scientific Corporation

Responsible Party: Boston Scientific Corporation Identifier: NCT02652481     History of Changes
Other Study ID Numbers: C1734
First Posted: January 12, 2016    Key Record Dates
Last Update Posted: November 20, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No